A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

ClinicalTrials.gov ID: NCT07247110

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07247110. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

Study identification

NCT ID: NCT07247110
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Enrollment: 250 participants

Conditions and interventions

Conditions

Malignant Neoplasm

Interventions

MK-4716 Drug
Pembrolizumab Biological
Cetuximab Biological

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2025 (Actual)
Primary completion: Dec 1, 2030 (Estimated)
Completion: Dec 1, 2030 (Estimated)
Last update posted: Oct 30, 2026

2025 – 2030

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Rutgers Cancer Institute of New Jersey ( Site 0052)	New Brunswick	New Jersey	08903	Recruiting
NEXT Oncology ( Site 0051)	Irving	Texas	75039	Recruiting
NEXT Virginia ( Site 0054)	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07247110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 30, 2026 · Synced Nov 14, 2026